PXL065
A novel stereoisomer of pioglitazone for the treatment of type 2 diabetes
PXL065 is a novel stereoisomer of the thiazolidinedione class of medications, specifically a deuterated form of pioglitazone. It is being developed for the treatment of type 2 diabetes mellitus, a chronic condition characterized by insulin resistance and high blood sugar levels.
Chemical Structure and Mechanism[edit | edit source]
PXL065 is a deuterated form of pioglitazone, which means that certain hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen. This modification is intended to improve the pharmacokinetic properties of the drug, potentially enhancing its efficacy and reducing side effects.
Pioglitazone, the parent compound, is a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It works by increasing the sensitivity of cells to insulin, thereby lowering blood glucose levels. PXL065 retains this mechanism of action but is designed to offer a more favorable safety profile.
Development and Clinical Trials[edit | edit source]
PXL065 is currently undergoing clinical trials to evaluate its safety and efficacy in patients with type 2 diabetes. The development of PXL065 is part of a broader effort to create improved versions of existing drugs through the use of deuteration, which can lead to better drug stability and reduced metabolism.
Potential Benefits[edit | edit source]
The use of deuterium in PXL065 aims to provide several potential benefits over traditional pioglitazone:
- Improved Metabolic Stability: Deuterium can slow the rate of drug metabolism, potentially leading to longer-lasting effects and reduced dosing frequency.
- Reduced Side Effects: By altering the metabolic pathway, PXL065 may reduce the risk of side effects commonly associated with pioglitazone, such as weight gain and fluid retention.
- Enhanced Efficacy: The improved pharmacokinetic profile may enhance the drug's ability to lower blood glucose levels effectively.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
